Literature DB >> 18977817

Neurosarcoidosis: a study of 30 new cases.

F G Joseph1, N J Scolding.   

Abstract

METHODS: The frequency, nature, relationship to systemic features, value of investigation findings and outcomes for a cohort of patients with neurosarcoidosis (NS) were studied by performing a retrospective survey of case records from nine District General or Regional Centre hospitals in south-west England and south Wales over a 12-year period (1990-2002). Thirty patients (29 Caucasians) were included--16 (53%) males and 14 (47%) females, including 13 with histological confirmation of CNS disease, making this one of the largest series of biopsy-confirmed NS; the remaining cases had "Probable" NS according to the Zajicek criteria. The male preponderance is of interest particularly considering the female predominance of systemic sarcoidosis.
RESULTS: The indicative prevalence of NS in this geographical area was estimated at one per 100,000, given an approximate population of 3 million. The most frequent features were headaches, visual failure, ataxia and vomiting. Cranial neuropathy occurred in 80% of patients, and as a presenting feature in 50%--though facial nerve involvement was seen in only 23%, and in none of those with definite disease. Unsurprisingly, no diagnostic clinical patterns emerged overall when only definite cases were analysed, but within our definite group of patients, meningeal and/or parenchymal lesion enhancement was observed in all but one case, while distinction from multiple sclerosis might also be aided by the observation that in all NS cerebrospinal fluid (CSF) samples with positive oligoclonal bands (27%), banding was accompanied by elevations of CSF protein.
CONCLUSION: From a prognostic perspective, the reported association of seizures in NS with a poor long-term outcome was not supported, while the suggestion that myelopathy also predicts an adverse prognosis was confirmed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18977817     DOI: 10.1136/jnnp.2008.151977

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  61 in total

1.  Neurosarcoidosis and the complexity in its differential diagnoses: a review.

Authors:  David R Spiegel; Kristyn Morris; Ubha Rayamajhi
Journal:  Innov Clin Neurosci       Date:  2012-04

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 3.  Cerebrospinal fluid and lumbar puncture: a practical review.

Authors:  Ben L C Wright; James T F Lai; Alexandra J Sinclair
Journal:  J Neurol       Date:  2012-01-26       Impact factor: 4.849

4.  Neurosarcoidosis presenting as spontaneously remitting hypersomnia.

Authors:  Yoshihiko Nakazato; Sayaka Kondo; Aya Ohkuma; Yasuo Ito; Naotoshi Tamura; Nobuo Araki
Journal:  J Neurol       Date:  2009-07-16       Impact factor: 4.849

Review 5.  Pediatric sellar and suprasellar lesions.

Authors:  Jason W Schroeder; L Gilbert Vezina
Journal:  Pediatr Radiol       Date:  2011-01-26

6.  A 54-year-old man with hallucinations and hearing loss.

Authors:  Claude Steriade; Steven L Shumak; Anthony Feinstein
Journal:  CMAJ       Date:  2014-06-30       Impact factor: 8.262

7.  Heerfordt's Syndrome Presenting with Recurrent Facial Nerve Palsy: Case report and 10-year literature review.

Authors:  Preetam Chappity; Rajeev Kumar; Anjan K Sahoo
Journal:  Sultan Qaboos Univ Med J       Date:  2015-01-21

8.  A rare comorbidity: neurosarcoidosis and cutaneous sarcoidosis.

Authors:  Lütfi Akyol; Kerim Aslan; Metin Özgen; Mehmet Sayarlioglu
Journal:  BMJ Case Rep       Date:  2015-11-17

9.  Neurosarcoidosis.

Authors:  Kenkichi Nozaki; Marc A Judson
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 10.  Extrapulmonary manifestations of sarcoidosis.

Authors:  Deepak A Rao; Paul F Dellaripa
Journal:  Rheum Dis Clin North Am       Date:  2013-03-13       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.